azn201605236k.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2016
Commission File Number: 001-11960
AstraZeneca PLC
2 Kingdom Street, London W2 6BD
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 23 May 2016, the interest of Luke Miels, a person discharging managerial responsibilities, in AstraZeneca PLC Ordinary Shares of $0.25 each changed as detailed below.
The change in interest relates to the vesting on 23 May 2016 of an award of shares granted in September 2014 under the AstraZeneca Restricted Share Plan. In accordance with the terms of the award, Mr Miels has become beneficially entitled to all of the shares originally awarded.
Sufficient vested shares have been withheld to cover certain tax obligations arising on the vesting and the net number of shares has been delivered into a personal brokerage account.
|
Plan
|
Shares awarded
|
Shares vested
|
Shares withheld
|
Net shares received
|
|
AstraZeneca Restricted Share Plan
|
7,776
|
7,776
|
2,524
|
5,252
|
For tax purposes, the fair market value of the shares at vest was 3894.5 pence per share being the closing price of AstraZeneca shares on the last trading day preceding the vesting day.
A C N Kemp
Company Secretary
23 May 2016
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AstraZeneca PLC
|
Date: 23 May 2016
|
By: /s/ Adrian Kemp
|
| |
Name: Adrian Kemp
|
| |
Title: Company Secretary
|